文献速递产科

实施质量改进措施以减少剖宫产术后阿片类药物处方

Implementation of a Quality Improvement Initiative to Decrease Opioid Prescribing After Cesarean Delivery.
PubMed 文献 · Obstet Gynecol · 2018-01-01

本前瞻性质量改进研究纳入624例剖宫产产妇,分阶段实施疼痛咨询、共同决策及调整阿片类药物最大处方量。第一阶段将阿片类药物片数从33.2片降至26.5片,第二阶段进一步降至21.5片,总体减少35%,且未影响30天内再开药率;对乙酰氨基酚处方率从32.6%升至92.0%。

要点

  • 分阶段质量改进方案使剖宫产术后阿片类药物处方片数从33.2片降至21.5片,总体减少35%。
  • 阿片类药物再开药率在干预前后无显著差异(8.9% vs 8.1%,P=.79;6.3% vs 5.1%,P=.72)。
  • 对乙酰氨基酚处方率从第一阶段前的32.6%升至第二阶段后的92.0%(P<.001)。

核心结论

  • 实施多阶段质量改进方案并结合出院数据迭代审查,可显著减少剖宫产术后阿片类药物处方片数。

研究设计与样本

  • 前瞻性质量改进研究,纳入624例剖宫产产妇,分两阶段实施干预并分析数据。

主要发现

  • 第一阶段实施后,出院时阿片类药物处方平均片数从33.2片(标准差9.3)降至26.5片(标准差6.7),P<.01。
  • 第一阶段后30天内阿片类药物再开药率为8.9% vs 8.1%,P=.79。
  • 第二阶段将最大推荐处方量调整为25片后,平均处方片数从24.9片(标准差7.5)进一步降至21.5片(标准差6.3),P<.01。
  • 第二阶段后30天内阿片类药物再开药率为6.3% vs 5.1%,P=.72。
  • 总体阿片类药物处方量减少35%(P<.01);布洛芬处方率全程≥98%,对乙酰氨基酚处方率从32.6%升至92.0%(P<.001)。

关键数值与推荐

  • 第一阶段允许患者选择最多30片5 mg羟考酮(或等效阿片类药物),低于既往常规出院处方40片。
  • 第二阶段将方案最大阿片类药物处方量调整为25片,其他方案内容未变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether a multiphase, departmental quality improvement effort decreases opioid prescribing and increases multimodal analgesic use after cesarean delivery. METHODS: This is a prospective quality improvement study. In phase 1 of the protocol, discharge providers implemented counseling regarding expectations for pain, typical need for opioids, and importance of multimodal nonopioid analgesic use and used shared decision-making to determine the number of opioids prescribed. Patients could select up to a maximum of 30 tablets of 5 mg oxycodone (or equivalent opioid), lower than the previous routine discharge prescription of 40 opioid tablets. The primary outcome was the mean (SD) number of opioid tablets prescribed on discharge with secondary outcomes including opioid refill rate within 30 days of discharge and rates of nonopioid analgesic prescriptions on discharge. In phase 2, using these results, we adjusted the protocol's maximum opioid prescription to 25 opioid tablets, but no other aspects of the protocol were changed. All data were analyzed with t test and χ analyses. RESULTS: Data from 624 women who underwent cesarean deliveries were analyzed. Opioids, most commonly oxycodone, were prescribed after 95% of all cesarean deliveries. The mean (SD) number of opioid tablets prescribed decreased from 33.2 (9.3) to 26.5 (6.7; P<.01) with the implementation of phase 1 having no effect on the opioid refill rate, 8.9% vs 8.1% (P=.79). These results allowed adjustment of the maximum recommended prescription to 25 opioid tablets, introducing phase 2 of the study, during which the mean (SD) number of opioid tablets prescribed further decreased from 24.9 (7.5) to 21.5 (6.3; P<.01) with no effect on the opioid refill rate, 6.3% vs 5.1% (P=.72). Overall, this represents a 35% decrease in opioid prescribing (P<.01). Rates of ibuprofen prescribing were 98% or higher throughout the study, but rates of acetaminophen prescribing increased from 32.6% before phase 1 to 92.0% after phase 2 (P<.001). CONCLUSION: Implementation of a multiphase quality improvement protocol to decrease opioid prescribing, combined with iterative review of discharge data, resulted in a significant decrease in the number of opioid tablets prescribed after cesarean delivery.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Prabhu M, Dubois H, James K, et al. Implementation of a Quality Improvement Initiative to Decrease Opioid Prescribing After Cesarean Delivery. Obstet Gynecol. 2018. PMID: 30095765. doi:10.1097/AOG.0000000000002789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。